Breast cancer is the most common malignancy in women; 60-74% of patients dying of breast cancer have pulmonary metastases and the lung is the only site of metastasis in 21 %.' 2 As many as 28% of lung metastases may be undetected before necropsy.2 These data from necropsy series, however, do not provide information about the clinical manifestations of breast cancer. This study was designed to find out the range of pulmonary metastases from breast cancer, the disease-free interval before their detection, and the prognosis after their discovery.
Methods
We reviewed the case records of all patients with a diagnosis of breast cancer (current Pericardial and myocardial metastases were usually necropsy findings and were not usually of clinical importance.
The thorax was often the initial site of tumour recurrence after surgery. The most common pattern observed was pleural metastasis, followed by mediastinal or hilar metastasis and/or pulmonary nodules (table 2). The initial thoracic recurrences were either multifocal or occurred simultaneously with other evidence of metastases. In only 10 instances was there a single focus of thoracic disease unaccompanied by other thoracic or extrathoracic metastatic disease. Tumour emboli, alveolar metastasis and pericardial and myocardial metastases were never the first location of metastasis from breast cancer.
The interval between the first diagnosis of breast cancer and the detection of an initial thoracic metastasis varied considerably. Although most recurrences appeared within five years, 13 patients first showed metastatic disease in the thorax 5-10 years after mastectomy and 12 others had an initial thoracic metastasis after an interval greater than 10 years. Thus 35% of all initial thoracic metastases had a disease-free interval greater than five years and in 17% it was longer than 10 years. Although no particular site was strikingly associated with a long disease-free interval, five of the 12 patients with The four patients who underwent resection of solitary pulmonary nodular metastases had remissions of nine, 41, 44, and 121 months. Two of these patients are currently disease free 44 and 121 months after surgery. Both patients who relapsed after surgery had recurrence of tumour within the lung.
Discussion
This study illustrates the range of thoracic metastases from breast cancer. The diagnosis of metastatic thoracic disease is often suspected because of a previous diagnosis of metastatic cancer, the simultaneous appearance of several intrathoracic foci, or the appearance of both thoracic and systemic disease. When a single focus of initial metastasis is present, prompt diagnosis and treatment may produce a complete response and prolonged survival. The 10 patients with a single focus of initial metastasis have a median survival of over 42 months, with three patients currently in remission.
Although most initial thoracic metastases occurred within five years, 18% occurred five to 10 years after diagnosis and 17% of initial thoracic metastases occurred more than 10 years after diagnosis. The longest disease-free interval before an initial metastasis was 16 years. Occasionally the thoracic metastasis is the only evidence of breast cancer and the primary lesion is detected after resection of the metastasis. 3 Lymphangitic metastasis was the most frequently observed pulmonary parenchymal manifestation. Although lymphangitic metastasis may be suspected from the history of progressive dyspnoea with or without a non-productive cough, and diffuse reticular infiltrates on the chest radiograph, a definitive diagnosis requires histopathological confirmation. The slow progression of tumour (and three complete remissions) in the group with a single detectable metastatic focus may be related to the small tumour burden and hence increased efficacy of either chemotherapy or hormonal treatment.'9 Alternatively, the long survival in this group may be explained by the long lead time and earlier diagnosis of a metastatic focus during the natural history of a slow-growing tumour. The problem of the initial solitary thoracic metastasis is a diagnostic challenge requiring histopathological confirmation. After diagnosis treatment may produce a sustained remission of disease.
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